Ser1607

Site Information
KRVYLsDsDNNsLET SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3213762

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:	breast cancer ( 3 , 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , cervical cancer ( 9 ) , cervical adenocarcinoma ( 9 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:	breast ( 1 ) , Calu 6 (pulmonary) ( 4 ) , H2009 (pulmonary) ( 4 ) , H2077 (pulmonary) ( 4 ) , H2887 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HCC1359 (pulmonary) ( 4 ) , HCC1937 (breast cell) ( 4 ) , HCC366 (pulmonary) ( 4 ) , HCC4006 (pulmonary) ( 4 ) , HCC78 (pulmonary) ( 4 ) , HCC827 (pulmonary) ( 4 ) , HeLa (cervical) ( 2 , 6 , 11 ) , HeLa S3 (cervical) ( 9 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , HOP62 (pulmonary) ( 4 ) , Jurkat (T lymphocyte) ( 5 , 7 , 8 , 10 ) , LCLC-103H (pulmonary) ( 4 ) , LOU-NH91 (squamous) ( 4 ) , MCF-7 (breast cell) ( 4 ) , NCI-H1395 (pulmonary) ( 4 ) , NCI-H1568 (pulmonary) ( 4 ) , NCI-H1648 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 4 ) , NCI-H322 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H647 (pulmonary) ( 4 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Guo A (2011) CST Curation Set: 11988; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS Curated Info
6	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
7	Possemato A (2010) CST Curation Set: 9072; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS Curated Info
8	Possemato A (2010) CST Curation Set: 9071; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)XpS Curated Info
9	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
10	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
11	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info